Tissue Regenix Group plc Financials

Market Capitalization £40.6 Million as of Jan. 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-2530.86
Forward PE	0.59
Price to Sales TTM	£1.46
Price to Book MRQ	£142.64
Enterprise to Revenue	1.60
Enterprise to EBITDA	104.78

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	-5.81%
Operating Margin	-1.04%
Return on Assets TTM	-0.55%
Return on Equity TTM	-5.55%

Income Statement

Revenue TTM	£23,492,059
Revenue per Share TTM	£0.42
Quarterly Revenue Growth	21.80%
Gross Profit TTM	£11,183,281
EBITDA	£355,252
Net Income to Common TTM	£-1,364,455
Diluted EPS TTM	£-0.02
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	£3,703,864
Total Cash per Share MRQ	£0.07
Total Debt MRQ	£
Total Debt to Equity MRQ	32.01
Current Ratio MRQ	4.03
Book Value per Share MRQ	£0.43

Cash Flow

Operating Cash Flow TTM	£828,391
Levered Free Cash Flow TTM	£-589,730

TRX Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	70,574,496
Float Shares	45,149,034
Avg 10 Volume	32,380
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	46.75%
% Held by Institutions	53.51%

Stock Price Summary

Beta	1.47
Fifty Two Week Low	£48.00
Fifty Two Week High	£72.94
Fifty Two Week Change	7.32%
Day 50 MA	£64.52
Day 200 MA	£57.25

Dividends and Splits

Forward Annual Dividend Rate	£
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	£0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2023-04-28